Pfizer and Mylan have agreed to settle litigation related to arthritis treatment Celebrex (celecoxib), Mylan announced today, June 2.
US-based drug company Acura and Novartis’s generic arm Sandoz have settled their patent infringement dispute related to an abuse-deterrent formulation of the painkiller Aversion (oxycodone).
The United Nations Development Programme has released a guidebook for low- to middle- income countries on how to increase access to essential health technologies and HIV treatments by using competition law and policy.
A US district court has dismissed Teva’s case against the FDA aimed at stopping the administration from approving generic versions of its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).
The English High Court has ruled that a patent covering vitamin dosage regimens for Eli Lilly’s lung cancer drug Alimta (pemetrexed disodium) would not be infringed by generic competitors.
Novartis and Sun Pharma’s US subsidiary have settled litigation related to cancer drug Gleevec (imatinib mesylate) in the US, the companies announced today (May 15).
Johnson & Johnson’s pharmaceuticals subsidiary Janssen has sued Mylan to stop it launching a generic version of Concerta (methylphenidate hydrochloride).
Canadian pharmaceutical company Valeant announced yesterday (May 12) that it had settled all litigation related to its acne treatment Acanya (clindamycin phosphate and benzoyl peroxide) with Actavis.
Acura Pharmaceuticals and Ranbaxy have agreed to settle their patent infringement litigation related to painkiller Aversion (oxycodone hydrochloride), once marketed by Pfizer under its registered trademark Oxecta.
The US Federal Trade Commission (FTC) has filed an amicus brief in an antitrust case that concerns a “no-authorised-generic” settlement between Teva and GlaxoSmithKline (GSK).